NEW
Stock Screener with Intrinsic Value
Royalty Pharma plc (RPRX)
Last Price$30.8(0.6%)
Market Cap$13.8B
LTM NOPAT
$1,268.1M
NOPAT margin
56.0%
5Y avg: 49.8%
EPV as % of EV
152.5%
Market-Implied Value of Growth,
MIVoG as % of EV
(52.5%)
Discount rate
4.5%
Stock quality
7/10
Good
RPRX Earnings Power Value Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
RPRX NOPAT
Crunching data... Almost there!
RPRX Earnings Power Value and Enterprise Value
Crunching data... Almost there!
RPRX vs Peer Set: Earnings Power Value comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for RPRX
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Royalty Pharma plc Earnings Power Value?
As of Sep 30, 2024, Royalty Pharma plc's Earnings Power Value is approximately $28.2B.
What is Royalty Pharma plc EV (Enterprise Value)?
As of Sep 30, 2024, Royalty Pharma plc's Enterprise Value (EV) estimates at $18.5B.
What is Royalty Pharma plc NOPAT?
As of Sep 30, 2024, Royalty Pharma plc's Net operating profit after tax (NOPAT) is approximately $1,268.1M.